These findings also encouraged further efforts to explore individualized treatment strategies that target immunological checkpoints PD-1 and Tim-3 and enhance the proliferation of CD8+ T cells, which may be able to repair ARDS-induced immunosuppression and protect the host from secondary infections. This evidence concerns the gene CD8A and acute respiratory distress syndrome.